Prothena Corporation plc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases caused by amyloid or cell adhesion. Prothena’s potential therapeutic monoclonal antibodies are directed specifically to disease causing proteins. Prothena’s antibody-based product candidates target a number of potential indications including AL and AA forms of amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and novel cell adhesion targets involved in psoriasis and other inflammatory diseases (PRX003).
Nov 3, 2014
Aug 26, 2014